Laurus Labs Limited — Q2FY27 earnings call summary

Filed 03 November 2026 · Official transcript

Multiple analyst queries on peptide capacity utilization, capex execution, and CDMO project pipeline
Capex INR 470 Cr in Q2, INR 864 Cr in H1; INR 3,000 Cr planned for FY27-28; net debt INR 2,466 Cr, debt/EBITDA 1.02
Peptide commercial revenues expected around 2029; capacity expansion planned due to early clinical programs
Asset turn target 1.1x-1.4x over time; peptide resin cost 10-20% of raw material cost
Q2 FY27 revenue INR 2,206 Cr; H1 INR 4,233 Cr, +31% y-y; EBITDA margin 34.5% in Q2, 33.2% in H1
No significant customer concentration; stable gross margin guidance >60%, EBITDA margin >30%
Laurus Bio fermentation facility commissioning Q4 FY27; commercial supplies from Q1 FY28
CDMO segment Q2 sales INR 875 Cr (+86% y-y), H1 INR 1,710 Cr (+77% y-y); peptide manufacturing capacity 16,000 liters